Stimulants and sudden death: What is a physician to do?

Pediatrics

Volumn 118, Issue 3, 2006, Pages 1215-1219

  Wilens, Timothy E ^a   Prince, Jefferson B ^a,b   Spencer, Thomas J ^a   Biederman, Joseph ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NORTH SHORE MEDICAL CENTER   (United States)

Author keywords

ADHD; Amphetamine; Attention deficit hyperactivity disorder; Blood pressure; Cardiovascular; Electrophysiology; Methylphenidate; Pulse; Stimulant; Sudden death

Indexed keywords

AMPHETAMINE; CENTRAL STIMULANT AGENT; METHYLPHENIDATE;

ARTICLE; ATTENTION DEFICIT DISORDER; CARDIOVASCULAR RISK; DISEASE SEVERITY; FOOD AND DRUG ADMINISTRATION; HEART ELECTROPHYSIOLOGY; HUMAN; PRIORITY JOURNAL; SIDE EFFECT; SUDDEN DEATH; VITAL SIGN; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; CHILD; DRUG EFFECT; ELECTROCARDIOGRAPHY; REVIEW; RISK FACTOR;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DEATH, SUDDEN, CARDIAC; ELECTROCARDIOGRAPHY; HUMANS; RISK FACTORS;

EID: 33749072081     PISSN: 00314005     EISSN: 02105721     Source Type: Journal    
DOI: 10.1542/peds.2006-0942     Document Type: Article

References (45)

1. Costello J, Angold A, Burns, et al. The Great Smoky Mountains Study of Youth: goals, design, methods, and the prevalence of DSM-III-R disorders. Arch Gen Psychiatry. 1996;53:1129-1136
2. Bauermeister JJ, Canino G, Bird H. Epidemiology of disruptive behavior disorders. In: Greenhill L, ed. Child and Adolescent Psychiatric Clinics of North America. Philadelphia, PA: WB Saunders; 1994:177-194
3. American Academy of Child and Adolescent Psychiatry. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2002;41(2 suppl):26S-49S
4. American Academy of Pediatrics, Subcommittee on Attention-Deficit/ Hyperactivity Disorder and Committee on Quality Improvement. Clinical practice guideline: treatment of the schoolaged child with attention-deficit/ hyperactivity disorder. Pediatrics. 2001;108:1033-1044
5. Wilens TE, Biederman J, Spencer TJ. Attention deficit/hyperactivity disorder across the lifespan. Annu Rev Med. 2002;53:113-131
6. Pliszka SR, Greenhill LL, Crismon ML, et al. The Texas Children's Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Attention-Deficit/Hyperactivity Disorder. Part I. Attention- deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2000;39:908-919
7. Nissen SE. ADHD drugs and cardiovascular risk. N Engl J Med. 2006;354:1445-1448
8. Aman MG, Werry JS. Methylphenidate in children: effects upon cardiorespiratory function on exertion. Int J Ment Health. 1975;4:119-131
9. Samuels JA, Franco K, Wan F, Sorof JM. Effect of stimulants on 24-h ambulatory blood pressure in children with ADHD: a double-blind, randomized, cross-over trial. Pediatr Nephrol. 2006;21:92-95
10. Wren C. Sudden death in children and adolescents. Heart. 2002;88:426-431
11. Berger S, Kugler JD, Thomas JA, Friedberg DZ. Sudden cardiac death in children and adolescents: introduction and overview. Pediatr Clin North Am. 2004;51:1201-1209
12. Basso C, Corrado D, Thiene G. Cardiovascular causes of sudden death in young individuals including athletes. Cardiol Rev. 1999;7:127-135
13. Van Camp SP, Bloor CM, Mueller FO, Cantu RC, Olson HG. Nontraumatic sports death in high school and college athletes. Med Sci Sports Exerc. 1995;27:641-647
14. Maron BJ, Shirani J, Poliac LC, Mathenge R, Roberts WC, Mueller FO. Sudden death in young competitive athletes: clinical, demographic, and pathological profiles. JAMA. 1996;276:199-204
15. Aman MG, Werry JS. The effects of methylphenidate and haloperidol on the heart rate and blood pressure of hyperactive children with special reference to time of reaction. Psychopharmacologia. 1975;43:163-168
16. Safer DJ. The relative cardiovascular safety of psychostimulants used to treat attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol. 1992;2:279-290
17. Findling RL, Short EJ, Manos MJ. Short-term cardiovascular effects of methylphenidate and Adderall. J Am Acad Child Adolesc Psychiatry. 2001;40:525-529
18. Brown RT, Sexson SB. A controlled trial of methylphenidate in black adolescents: attentional, behavioral, and physiological effects. Clin Pediatr (Phila). 1988;27:74-81
19. Wilens TE, Biederman J, Lerner M; Concerta Study Group. Effects of once-daily osmotic-release methylphenidate on blood pressure and heart rate in children with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2004;24:36-41
20. Stowe CD, Gardner SF, Gist CC, Schulz EG, Wells TG. 24-hour ambulatory blood pressure monitoring in male children receiving stimulant therapy. Ann Pharmacother. 2002;36:1142-1149
21. Wilens T, McBurnett K, Stein M, Lerner M, Spencer T, Wolraich M. ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry. 2005;44:1015-1023
22. Biederman J, Quinn D, Weiss M, et al. Efficacy and safety of Ritalin LA, a new, once-daily, extended-release dosage form of methylphenidate hydrochloride, in children with ADHD. Paediatr Drugs. 2003;5:833-841
23. Biederman J, Lopez FA, Boellner SW, Chandler MC. A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder. Pediatrics. 2002;110:258-266
24. Wilens T, Spencer T, Biederman J. Short- and long-term cardiovascular effects of mixed amphetamine salts extended-release in adolescents with ADHD. CNS Spectr. 2005;10:22-30
25. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children With ADHD. Arch Gen Psychiatry. 1999;56:1073-1086
26. Wigal S, Swanson JM, Feifel D, et al. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2004;43:1406-1414
27. Findling RL, Biederman J, Wilens T, et al. Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children. J Pediatr. 2005;147:348-354
28. Weisler RH, Biederman J, Spencer TJ, Wilens TE. Long-term cardiovascular effects of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr. 2005;10:35-43
29. Spencer T, Biederman J, Wilens T, et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005;57:456-463
30. Wilens T, Hammerness P, Biederman J, et al. Blood pressure changes associated with medication treatment of adults with attention-deficit/ hyperactivity disorder. J Clin Psychiatry. 2005;66:253-259
31. Wilens TE, Spencer T. The stimulants revisited. In: Stubbe C, ed. Child and Adolescent Psychiatric Clinics of North America. 3rd ed. Philadelphia, PA: Saunders; 2000:573-603
32. Garson A, Bricker JT, McNamara DG. The Science and Practice of Pediatric Cardiology. Philadelphia, PA: Lea and Febiger; 1990
33. Wolraich ML, Greenhill LL, Pelham W, et al. Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/ hyperactivity disorder. Pediatrics. 2001;108:883-892
34. Weiss G, Hechtman L, Milroy T, Perlman T. Psychiatric status of hyperactives as adults: a controlled prospective 15-year followup of 63 hyperactive children. J Am Acad Child Psychiatry. 1985;24:211-220
35. Mannuzza S, Klein R, Bessler A, Malloy P, LaPadula M. Adult psychiatric status of hyperactive boys grown up. Am J Psychiatry. 1998;155:493-498
36. Biederman J, Monuteaux M, Mick E, et al. Young adult outcome of attention deficit hyperactivity disorder: a controlled 10 year prospective follow-up study. Psychol Med. 2006;36:167-179
37. Barkley RA, Murphy KR, Dupaul GI, Bush T. Driving in young adults with attention deficit hyperactivity disorder: knowledge, performance, adverse outcomes, and the role of executive functioning. J Int Neuropsychol Soc. 2002;8:655-672
38. Cox DJ, Merkel L, Penberthy JK, Kovatchev B, Hankin CS. Impact of methylphenidate delivery profiles on driving performance of adolescents with attention-deficit/hyperactivity disorder: a pilot study. J Am Acad Child Adolesc Psychiatry. 2004;43:269-275
39. Milberger S, Biederman J, Faraone S, Chen L, Jones J. ADHD is associated with early initiation of cigarette smoking in children and adolescents. J Am Acad Child Adolesc Psychiatry. 1997;36:37-44
40. Wilens TE, Biederman J, Mick E, Faraone SV, Spencer T. Attention deficit hyperactivity disorder (ADHD) is associated with early onset substance use disorders. J Nerv Ment Dis. 1997;185:475-482
41. Wilens T, Faraone S, Biederman J, Gunawardene S. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics. 2003;111:179-185
42. Monuteaux MC, Biederman J, Spencer T. A randomized, double-blind, placebo-controlled clinical trial of bupropion for the prevention of smoking in youth with attention deficit-hyperactivity disorder. Presented at: NCI Tobacco Investigators Meeting: Synthesizing Research for the Public's Health; San Diego, CA; June 2-4, 2004
43. Goldman L, Genel M, Bezman RJ, Slanetz PJ. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. JAMA. 1998;279:1100-1107
44. Gutgesell H, Atkins D, Barst R, et al. Cardiovascular monitoring of children and adolescents receiving psychotropic drugs. Circulation. 1999;99:979-982
45. Greenhill L, Osman B. Ritalin: Theory and Practice. New York, NY: Mary Ann Liebert; 1999